Severe Asthma Where Eosinophilic Granulomatosis with Polyangiitis Became Apparent after the Discontinuation of Dupilumab
Miki Ikeda, Nobuharu Ohshima, Masahiro Kawashima, Meiko Shiina, Masashi Kitani, Maho Suzukawa
Abstract
The use of biologic agents has enabled control of severe asthma, but there is a risk that eosinophilic granulomatosis with polyangiitis (EGPA) may be masked in some cases. We herein report a 71-year-old man who was administered dupilumab for 2 years to stabilize his asthma symptoms. A few months after discontinuation of dupilumab administration, an increase in the eosinophil count in peripheral blood, leg pain, and a rash appeared. Based on pathology, he was diagnosed with EGPA. EGPA in this case was considered to have become apparent due to the discontinuation of dupilumab administration.
Topics & Concepts
DupilumabMedicineGranulomatosis with polyangiitisDiscontinuationEosinophilicAsthmaDermatologyRashBenralizumabEosinophilMepolizumabVasculitisMicroscopic polyangiitisInternal medicinePathologyDiseaseAsthma and respiratory diseasesAllergic Rhinitis and SensitizationUrticaria and Related Conditions